Shaker Dakhil

Shaker Dakhil

UNVERIFIED PROFILE

Are you Shaker Dakhil?   Register this Author

Register author
Shaker Dakhil

Shaker Dakhil

Publications by authors named "Shaker Dakhil"

Are you Shaker Dakhil?   Register this Author

100Publications

2994Reads

36Profile Views

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.

N Engl J Med 2019 03;380(13):1226-1234

From the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange (R.S.M.); the SWOG Statistics and Data Management Center (W.E.B., D.L.L.) and Seattle Cancer Care Alliance and University of Washington Medical Center (J.R.G., H.H.L.) - both in Seattle; Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); London Health Sciences Centre and the National Cancer Institute of Canada Clinical Trials Group, London, ON, Canada (T.A.V.); the Cancer Center of Kansas and Wichita National Cancer Institute Community Oncology Research Program (NCORP), Wichita (S.R.D.); Kaiser Permanente NCORP, Portland, OR (N.R.T.); the University of Michigan, Ann Arbor (D.F.H.); the University of Arizona Cancer Center, Tucson (R.B.L.); and the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1811714DOI Listing
March 2019

Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study.

J Clin Oncol 2018 Sep 21:JCO2018786624. Epub 2018 Sep 21.

Michelle C. Janelsins, Charles E. Heckler, Luke J. Peppone, Supriya G. Mohile, Karen M. Mustian, Annalynn M. Williams, Allison Magnuson, and Gary R. Morrow, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester; Tim A. Ahles, Memorial Sloan Kettering Cancer Center, New York, NY; Oxana Palesh, Stanford Cancer Center, Stanford, CA; Ann M. O'Mara and Lori M. Minasian, National Cancer Institute (NCI), National Institutes of Health, Rockville, MD; Jodi Geer, Metro Minnesota NCI Community Oncology Research Program (NCORP), Saint Louis Park, MN; Shaker R. Dakhil, Wichita NCORP, Wichita, KS; and Judith O. Hopkins, Southeast Clinical Oncology Research Consortium NCORP, Winston-Salem, NC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.6624
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.6624DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225503PMC
September 2018

Metastasis of Benign Leiomyomas Outside the Uterus.

Kans J Med 2018 May 18;11(2):1-11. Epub 2018 May 18.

Wesley Medical Center, Wichita, KS.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962322PMC
May 2018

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

J Clin Oncol 2018 03 22;36(7):697-703. Epub 2018 Jan 22.

Mazyar Shadman, Ajay K. Gopal, David G. Maloney, and Oliver W. Press, University of Washington and Fred Hutchinson Cancer Research Center; Hongli Li and Michael LeBlanc, SWOG Statistical Center, Seattle, WA; Lisa Rimsza, Mayo Clinic Arizona, Scottsdale; Catherine M. Spier, University of Arizona, Tucson, AZ; John P. Leonard, Weill Cornell Medical College, New York; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; Mark S. Kaminski, University of Michigan Health System, Ann Arbor, MI; Rita M. Braziel, Oregon Health & Science University, Portland, OR; Bruce D. Cheson, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC; Shaker Dakhil, University of Kansas School of Medicine-Wichita, Wichita, KS; Sonali M. Smith, University of Chicago Medicine, Chicago, IL; and Richard I. Fisher, Fox Chase Cancer Center and Temple University School of Medicine, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.5083
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.5083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553811PMC
March 2018

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

J Clin Oncol 2017 Mar 30;35(8):885-892. Epub 2017 Jan 30.

Sanjiv S. Agarwala, Saint Luke's University Hospital, Easton; Uma N. Rao, Ahmad A. Tarhini, Terry L. Evans, and John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; Sandra J. Lee, and Waiki Yip, Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA; Gary I. Cohen, Greater Baltimore Medical Center, Baltimore, MD; Douglas S. Reintgen, Lakeland Regional Cancer Center, Lakeland; Vernon K. Sondak, H. Lee Moffitt Cancer Center, Tampa, FL; Joanna M. Brell, MetroHealth Medical Center, Cleveland; William E. Carson, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Mark R. Albertini, University of Wisconsin Hospital, Madison, WI; Michael B. Atkins, Georgetown Medical Center, Washington, DC; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; Robert M. Conry, University of Alabama at Birmingham, Birmingham, AL; Jeffrey A. Sosman, Vanderbilt University, Nashville; Alberto S. Pappo, Saint Jude Children's Research Hospital Oncology, Memphis, TN; Lawrence E. Flaherty, Wayne State University/Karmanos Cancer Institute, Detroit, MI; Michael G. Smylie, Cross Cancer Institute, Edmonton, Canada; and Richard F. Kefford, Sydney West Area Health Service, Westmead, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.2951DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455684PMC
March 2017

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

J Clin Oncol 2017 02 14;35(6):591-597. Epub 2016 Nov 14.

Toni K. Choueiri and Meghara K. Walsh, Dana-Farber Cancer Institute; M. Dror Michaelson, Massachusetts General Hospital Cancer Center, Boston, MA; Susan Halabi and Ben L. Sanford, Alliance Statistics and Data Center and Duke University; Daniel J. George, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Olwen Hahn, Alliance Protocol Operations Office, Chicago, IL; Darren R. Feldman and Michael J. Morris, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas Olencki, Ohio State University Medical Center, Columbus, OH; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Eric J. Small, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; and Shaker Dakhil, University of Kansas Wichita, Wichita, KS.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.7398DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455807PMC
February 2017

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

J Clin Oncol 2016 10;34(30):3609-3617

Cyrille Hulin, Bordeaux Hospital University Center, Bourdeaux; Philippe Rodon, Centre Hospitalier de Périgueux, Périgueux; Brigitte Pégourié, Centre Hospitalier Regional Universitaire, Grenoble; Laurent Garderet, Centre Hospitalier Universitaire (CHU) Hôpital St-Antoine, Paris; Isabelle Azais, CHU Institut National de la Santé et de la Recherche Médicale (INSERM); Xavier Leleu, Hôpital de la Milétrie, CHU INSERM, Poitiers; Margaret Macro, CHU de Caen, Caen; Bruno Royer, University Hospital, Amiens; Thierry Facon, Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Andrew Belch, Cross Cancer Institute, Edmonton, Alberta; Chaim Shustik, Royal Victoria Hospital; Richard LeBlanc, Hôpital Maisonneuve-Rosemont, Montreal, Quebec; Kevin Song, Vancouver General Hospital, Vancouver, British Columbia, Canada; Maria Teresa Petrucci, Azienda Policlinico Umberto I, University La Sapienza, Rome, Italy; Ulrich Dührsen, University Hospital of Essen, West German Cancer Center, Essen, Germany; Jin Lu, Peking University Institute of Hematology, People's Hospital, Beijing, China; Hannah Hunter, Derriford Hospital, Plymouth, United Kingdom; Richard Eek, Border Medical Oncology, Wodonga, Victoria, Australia; Heinz Gisslinger, Medizinische Universität Wien, Vienna, Austria; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Cristina Goncalves, Hospital de Santo Antonio-Porto, Porto, Portugal; Ken Romeril, Wellington Hospital, Wellington, New Zealand; Chantal Doyen, Université Catholique de Louvain (UCL), CHU UCL Namur, Yvoir; Fritz Offner, Universitair Ziekenhuis Gent, Ghent, Belgium; Nicolas Leupin, Celgene International, Boudry, Switzerland; Vanessa Houck, Guang Chen, and Annette Ervin-Haynes, Celgene, Summit, NJ; and Meletios A. Dimopoulos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.7295DOI Listing
October 2016

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.

Support Care Cancer 2016 Mar 23;24(3):1219-26. Epub 2015 Aug 23.

Department of General Internal Medicine, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-015-2915-2DOI Listing
March 2016

Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study.

Support Care Cancer 2016 Mar 2;24(3):1339-47. Epub 2015 Sep 2.

University of Rochester Cancer Center Community Clinical Oncology Program Research Base, Behavioral Medicine Unit, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-015-2903-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731275PMC
March 2016

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 Mar 25;34(9):953-62. Epub 2016 Jan 25.

Suresh Senan, VU Medical Center, Amsterdam; Bonne Biesma, Jeroen Bosch Hospital, 's-Hertogenbosch; and Joachim Aerts, Erasmus MC Rotterdam/Amphia Hospital Breda, Breda, the Netherlands; Anthony Brade, Princess Margaret Hospital, University of Toronto; Neill Iscoe, Eli Lilly Canada, Toronto, Ontario, Canada; Lu-hua Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Tony Mok, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, People's Republic of China; Johan Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Ramaswamy Govindan, Washington University School of Medicine, Saint Louis, MO; David Gandara, University of California, Davis Health System, Sacramento, CA; Hak Choy, UT Southwestern Medical Center, Dallas, TX; Anwar Hossain, Joseph Treat, and Andrew Koustenis, Eli Lilly and Company, Indianapolis, IN; Everett Vokes, University of Chicago, Chicago, IL; Maite Martinez Aguillo, Hospital of Navarre, Irunlarrea, Pamplona; Belén Rubio-Viqueira, Hospital Universitario Quirón Madrid; and Bélen San Antonio, Eli Lilly and Company, Madrid, Spain; Conrad Lewanski, Charing Cross Hospital, London, United Kingdom; and Nadia Chouaki, Eli Lilly and Company, Neuilly-sur-Seine, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8824DOI Listing
March 2016

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

J Clin Oncol 2016 Feb 26;34(5):419-26. Epub 2015 Oct 26.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; David Chen, Tetiana Taran, and David Lebwohl, Novartis Pharmaceuticals, East Hanover, NJ; Martine Piccart and Fabienne Lebrun, Université Libre de Bruxelles, Brussels; Ines Deleu, Oncology Centre, AZ Nikolaas, Sint-Nikolaas, Belgium; Hope S. Rugo, University of California, San Francisco; Ian Anderson, Redwood Regional Oncology Center, Santa Rosa, CA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Mario Campone, Centre de Recherche en Cancerologie, Nantes-Saint-Herblain; Thomas Bachelot, Centre Léon Bérard, Lyon, France; Shinzaburo Noguchi, Osaka University Medical School; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Alejandra T. Perez, Memorial Cancer Institute, Hollywood, FL; Mikhail Shtivelband, Ironwood Cancer & Research Centers, Chandler, AZ; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Douglas M. Robinson, Wei He, Abhishek Garg, E. Robert McDonald III, Hans Bitter, and Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070556PMC
February 2016

Modafinil Moderates the Relationship Between Cancer-Related Fatigue and Depression in 541 Patients Receiving Chemotherapy.

J Clin Psychopharmacol 2016 Feb;36(1):82-5

From the *Department of Psychology, Ohio State University, Columbus, OH; †Cancer Control, Department of Surgery, University of Rochester Medical Center, Rochester, NY; and ‡Hematology/Oncology Associates of Central New York, Syracuse, NY; §Dayton Community Clinical Oncology Program, Dayton, OH; ∥Wichita Community Clinical Oncology Program, Wichita, KS; and ¶Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/JCP.0000000000000442DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689625PMC
February 2016

Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).

J Clin Oncol 2015 Oct 17;33(30):3416-22. Epub 2015 Aug 17.

Deirdre R. Pachman, Rui Qin, Drew K. Seisler, Andreas S. Beutler, Lauren E. Ta, Jacqueline M. Lafky, Kathryn J. Ruddy, Nathan P. Staff, Axel Grothey, and Charles L. Loprinzi, Mayo Clinic, Rochester, MN; Ellen M.L. Smith, University of Michigan, Ann Arbor, MI; Nina D. Wagner-Johnston, Washington University School of Medicine, Saint Louis, MO; and Shaker Dakhil, Cancer Center of Kansas, Wichita, KS.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.8533DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606060PMC
October 2015

North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.

Menopause 2015 Jun;22(6):627-32

From the 1Virginia Commonwealth University, Richmond, VA; 2Alliance Statistics and Data Center, Mayo Clinic Rochester, Rochester, MN; 3Johns Hopkins Medical Institutions, Baltimore, MD; 4University of Michigan School of Nursing, Ann Arbor, MI; 5Colorado Cancer Research Program, Denver, CO; 6Wichita Community Clinical Oncology Program, Wichita, KS; 7Metro-Minnesota Community Clinical Oncology Program, St Louis Park, MN; 8Michigan Cancer Research Consortium, Ann Arbor, MI; 9Illinois Oncology Research Association Community Clinical Oncology Program, Peoria, IL; 10Grand Rapids Clinical Oncology Program, Grand Rapids, MI; and 11Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/GME.0000000000000374DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442087PMC
June 2015

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

J Clin Oncol 2015 Jun 6;33(17):1895-901. Epub 2015 Apr 6.

Melinda L. Telli, Kristin C. Jensen, Shaveta Vinayak, Allison W. Kurian, Jafi A. Lipson, Patrick J. Flaherty, Elizabeth A. Schackmann, Irene L. Wapnir, Robert W. Carlson, Pei-Jen Chang, and James M. Ford, Stanford University School of Medicine, Stanford; Bobbie Head, Marin Specialty Care, Greenbrae, CA; Kirsten Timms, Victor Abkevich, Julia E. Reid, and Anne-Renee Hartman, Myriad Genetics, Salt Lake City, UT; Joseph A. Sparano, Albert Einstein College of Medicine, New York, NY; Lori J. Goldstein, Fox Chase Cancer Center, Philadelphia, PA; Barbara Haley, University of Texas Southwestern Medical Center, Dallas, TX; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; and Judith Manola, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.0085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451172PMC
June 2015

Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.

J Clin Oncol 2015 Jun 4;33(17):1910-7. Epub 2015 May 4.

Dawn L. Hershman, Katherine D. Crew, Danielle Awad, and Heather Greenlee, Columbia University Medical Center, New York, NY; Joseph M. Unger, Danika L. Lew, and Cathee Till, Southwest Oncology Group Statistical Center; Joseph M. Unger, Julie Gralow, Danika L. Lew, Cathee Till, and Carol M. Moinpour, Fred Hutchinson Cancer Research Center, Seattle, WA; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; Lori M. Minasian, National Cancer Institute, Bethesda, MD; James L. Wade III, Central Illinois Community Clinical Oncology Program/Cancer Care Specialists of Central Illinois, Decatur, IL; and Frank L. Meyskens, University of California at Irvine, Chao Family Comprehensive Cancer Center, Orange, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.59.5595
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.5595DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451174PMC
June 2015

Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

N Engl J Med 2015 Mar;372(10):923-32

From the Cleveland Clinic Foundation, Cleveland (H.C.F.M.); SWOG Cancer Research Group Statistical Center, Fred Hutchinson Cancer Research Center (J.M.U., W.E.B.), and Seattle Cancer Care Alliance and University of Washington (J.G.) - all in Seattle; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC (K.-A.P., P.A.F.), Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) (K.-A.P., P.A.F., J.F.F.), Calvary Mater Hospital, Newcastle, NSW (F.B., J.M.L., J.F.F.), and University of Sydney, Sydney (F.B.) - all in Australia; International Breast Cancer Study Group (IBCSG), Bern, Switzerland (K.-A.P., P.A.F.); National Institute of Oncology, Budapest, Hungary (E.H.); Auckland Regional Cancer and Blood Service, Auckland, New Zealand (D.P.); Fox Chase Cancer Center, Philadelphia (L.J.G.); Instituto de Enfermedades Neoplasicas (H.L.G.) and Oncosalud SAC (C.S.V.), Lima, Peru; Dana-Farber Cancer Institute (A.H.P., R.D.G.) and IBCSG Statistical Center (R.D.G.) - both in Boston; Wichita Community Clinical Oncology Program, Wichita (S.R.D.), and University of Kansas, Westwood (C.J.F.) - both in Kansas; University of Southern California Norris Cancer Center, Los Angeles (A.A.G.), the Angeles Clinic and Research Institute, Santa Monica (S.M.), and University of California at Irvine Chao Family Comprehensive Cancer Center, Orange (F.L.M) - all in California; National Cancer Institute, Division of Cancer Prevention, Bethesda, MD (L.M.); M.D. Anderson Cancer Center, Houston (G.N.H.); and Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL (K.S.A.).

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/obgynsurvey/2015/06000/Gosereli
Web Search
http://www.nejm.org/doi/abs/10.1056/NEJMoa1413204
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1413204DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405231PMC
March 2015

Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.

Oncologist 2014 May 7;19(5):492-7. Epub 2014 Apr 7.

Mayo Clinic, Rochester, Minnesota, USA, Medical Oncology and Hematology Associates, Des Moines, Iowa, USA; Genomic Health, Inc., Redwood City, California, USA; Alegent Bergan Mercy Cancer Center, Omaha, Nebraska, USA; Cancer Center of Kansas, Wichita, Kansas, USA; Toledo Clinic, Toledo, Ohio, USA; Columbus Oncology Associates, Columbus, Ohio, USA; Mayo Clinic, Jacksonville, Florida, USA; Sanford Hospital, Sioux Falls, South Dakota, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2013-0401DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012966PMC
May 2014

Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).

J Clin Oncol 2014 Apr 2;32(10):997-1005. Epub 2013 Dec 2.

Charles L. Loprinzi, Rui Qin, Pamela Atherton, Drew Seisler, and Axel Grothey, Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; Shaker R. Dakhil, Wichita Community Clinical Oncology Program, Wichita, KS; Louis Fehrenbacher, Kaiser Permanente-Vallejo, Vallejo, CA; Kathleen A. Flynn, Michigan Cancer Research Consortium, Ann Arbor, MI; Rubina Qamar, Aurora Cancer Care-Milwaukee West, Wauwatosa, WI; and Grant C. Lewis, Summit Cancer Care, Savannah, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.0536DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965262PMC
April 2014

A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

Clin Cancer Res 2013 Dec 15;19(23):6624-32. Epub 2013 Oct 15.

Authors' Affiliations: Clinical Research Division; SWOG Statistical Center, Fred Hutchinson Cancer Research Center; Medical Oncology, University of Washington Medical Center, Seattle, Washington; Department of Pathology; Arizona Cancer Center, University of Arizona, Tucson, Arizona; James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester; Roswell Park Cancer Institute, Buffalo, New York; Cancer and Leukemia Group B; University of Michigan, Ann Arbor, Michigan; Department of Pathology, Oregon Health and Science University, Portland, Oregon; Georgetown University Hospital, Washington; Wichita Community Clinical Oncology Program, Wichita, Kansas; and Fox Chase Cancer Center-Temple Health, Temple University, Philadelphia PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1120DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872052PMC
December 2013

Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.

J Thorac Oncol 2013 Dec;8(12):1519-28

*Levine Cancer Institute, Charlotte, North Carolina; †SWOG Statistical Center, Seattle, Washington; ‡Yale Cancer Center, New Haven, Connecticut; §Cancer Center of Kansas and Wichita CCOP, Wichita, Kansas; ‖Central Illinois CCOP and Cancer Care Specialists, Decatur, Illinois; ¶University of Colorado Cancer Center, Aurora, Colorado; #University of California Davis Cancer Center, Sacramento, California; and **MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072123PMC
December 2013

Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer.

J Thorac Oncol 2013 Oct;8(10):1308-16

*University of Texas Southwestern, Dallas, Texas; †ACORN and West Clinic, Memphis, Tennessee; ‡Cancer Center of Kansas, Wichita, Kansas; §UCLA/Translational Oncology Research International Network, Los Angeles, Los Angeles; ‖Alamance Regional Medical Center, Burlington, North Carolina; ¶Washington University, St. Louis, Missouri; and #Lilly USA, LLC, Indianapolis, Indiana.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a02546DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715866PMC
October 2013

Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).

J Thorac Oncol 2013 Aug;8(8):1075-83

Department of Medical Oncology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182937317DOI Listing
August 2013

Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.

J Clin Oncol 2012 Sep 20;30(27):3389-95. Epub 2012 Aug 20.

University of Rochester Cancer Center Community Clinical Oncology Program Research Base, University of Rochester Medical Center, Rochester, NY 14642, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2011.39.8123
Publisher Site
http://dx.doi.org/10.1200/JCO.2011.39.8123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3438235PMC
September 2012

Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients.

Support Care Cancer 2012 Jul 5;20(7):1479-89. Epub 2011 Aug 5.

Departments of Dermatology, University of Rochester Medical Center, 601 Elmwood Ave, Box 697, Rochester, NY 14642, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-011-1236-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361530PMC
July 2012

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial.

Breast Cancer Res Treat 2012 Jun 14;133(3):1067-75. Epub 2012 Mar 14.

Magee Women's Hospital, University of Pittsburgh School of Medicine, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-012-2008-6
Publisher Site
http://dx.doi.org/10.1007/s10549-012-2008-6DOI Listing
June 2012

A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.

Clin Colorectal Cancer 2010 Apr;9(2):102-7

Center for Cancer and Blood Disorders, Bethesda, MD 20817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CCC.2010.n.014DOI Listing
April 2010

Melanoma metastatic to the duodenum presenting as upper GI bleed: 2 cases and a review of the literature.

Gastrointest Endosc 2008 May 31;67(6):998-1000. Epub 2008 Jan 31.

Department of Medicine, University of Kansas School of Medicine-Wichita, Kansas, Wichita, Kansas 67214, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gie.2007.09.045DOI Listing
May 2008

Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.

J Clin Oncol 2008 Mar 28;26(8):1223-30. Epub 2008 Jan 28.

School of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 650 Charles Young Dr South, Room A2-125 CHS, Los Angeles, CA 90095-6900, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.11.8877DOI Listing
March 2008

Von Meyenberg complexes simulating diffuse liver metastasis in rectal carcinoma.

Med J Aust 2007 Sep;187(5):305

Kansas University School of Medicine-Wichita, Wichita, KS, USA.

View Article

Download full-text PDF

Source
September 2007